Monoclonal Antibodies for C4.4a Detection in FFPE Tissue
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective monoclonal antibodies specifically adapted for immunohistochemistry assays, particularly for detecting C4.4a in formalin-fixed paraffin-embedded tissue samples, due to challenges in producing antibodies that bind to the uPAR-like domains of C4.4a, which are similar to its rabbit counterpart, and previous antibodies have not performed well in diagnostic applications.
Innovation Solution
Development of monoclonal C4.4a antibodies, such as clones S42H9L5 and S20H1L1, that specifically bind to epitopes within the uPAR-like domains of C4.4a, along with a host cell expression system and kits for immunohistochemistry, enabling detection in FFPE samples using chromogenic or fluorescence systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polyclonal C4.4a antibodies are used, then detection coverage is improved, but manufacturing precision and consistency deteriorate
Solution Approach 1:
The patent segments the polyclonal antibody population into multiple monoclonal antibody lines (e.g., 1G10, 1G11, 1G12) that each target specific epitopes on C4.4a. This segmentation allows for standardized production of individual monoclonal antibodies while maintaining comprehensive detection coverage through the combination of multiple specificities.
Solution Approach 2:
The patent changes the fundamental parameter of antibody type from polyclonal to monoclonal, enabling precise control over antibody production parameters. Monoclonal antibodies can be produced through hybridoma technology or recombinant methods with defined genetic sequences, ensuring batch-to-batch consistency while maintaining reliable detection performance.
2Measurement precision
If hybridoma techniques are used to produce monoclonal antibodies, then specificity is improved, but productivity and stability deteriorate
Solution Approach 1:
The patent creates stable copies of successful hybridoma cell lines through detailed characterization and documentation of their antibody-producing capabilities. Multiple monoclonal antibody lines (1G10, 1G11, 1G12) represent replicated successful clones that can be produced consistently through established protocols, ensuring both specificity and productivity.
Solution Approach 2:
The patent performs preliminary screening and selection of hybridoma clones during the development phase to identify those with optimal stability and productivity characteristics before full-scale production. This preliminary action ensures that only the most stable and productive clones are selected for diagnostic application, preventing later productivity issues.
3Measurement precision
If antibodies target uPAR-like domains of C4.4a, then diagnostic specificity for human C4.4a is improved, but cross-reactivity with rabbit C4.4a increases
Solution Approach 1:
The patent applies local quality by targeting specific epitopes within the uPAR-like domains of C4.4a that exhibit human-specific characteristics. The monoclonal antibodies are selected and characterized to recognize particular local regions (e.g., amino acid sequences) that maintain high specificity for human C4.4a while minimizing cross-reactivity with rabbit homologs, despite the overall structural similarity between species.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibodies effectively detect C4.4a in various cancer types, including lung, cervical, and skin cancers, providing a diagnostic tool for C4.4a-associated tumors with improved specificity and sensitivity in immunohistochemistry assays.
Implementation Method 1
monoclonal C4.4a antibodies, methods of detecting C4.4a using the monoclonal antibodies disclosed herein
Data Source
AI summary
Antibodies, compositions, systems, and methods for detecting C4.4a, for example immunohistochemistry methods for detecting C4.4a using a C4.4a antibody. The antibody may be obtained by immunizing a host with a C4.4a protein such as a peptide downstream of the signal peptide. The antibodies may be adapted to detect the uPAR-like domain 1 and uPAR-like domain 2. Also featured are methods for diagnosing C4.4a-associated tumors using C4.4a antibodies disclosed herein.